| Literature DB >> 30788262 |
Peter D Hart1,2, Diona J Buck1.
Abstract
Background: Resistance training (RT) is recommended as part of our national physical activity guidelines which includes working all major muscle groups on two or more days a week.Older adults can gain many health benefits from RT, such as increased muscle strength,increased muscle mass, and maintenance of bone density. Additionally, certain dimensions of health-related quality of life (HRQOL) have been shown to improve in older adults due to RT intervention. The purpose of this study was to use systematic review and meta-analytic techniques to examine the effect of RT on HRQOL in older adults.Entities:
Keywords: Health-related quality of life; Meta-analysis; Resistance training; SF-36; Systematic review
Year: 2019 PMID: 30788262 PMCID: PMC6377696 DOI: 10.15171/hpp.2019.01
Source DB: PubMed Journal: Health Promot Perspect ISSN: 2228-6497
Figure 1Characteristics of included meta-analysis studies
|
|
|
|
|
|
|
|
|
|
|
| Fanning J[ | 2017 | PCS | SF-12 | 66.9 | 60+ | Both | Obese | 24 | Yes |
| Ericson H[ | 2017 | MCS, PCS | SF-12 | 67.5 | 65+ | Female | Healthy | 24 | No |
| Vasconcelos KS[ | 2016 | PF | SF-36 | 72.0 | 65+ | Female | Sarcopenic obese | 10 | No |
| Tomas-Carus P[ | 2016 | BP, ERF, GH, MH, PF, PRF, SF, VT | SF-36 | 59.9 | 50+ | Both | Diabetic | 12 | Yes |
| Socha M[ | 2016 | BP, ERF, GH, MH, PF, PRF, SF, VT, PCS, MCS | SF-36 | 62.5 | 50+ | Female | PM | 8 | No |
| Winters-Stone KM[ | 2016 | MCS, PCS, PF, VT | SF-36 | 70.6 | 60+ | Both | Healthy | 24 | No |
| Burich R[ | 2015 | BP, ERF, GH, MH, PF, PRF, SF, VT, PCS, MCS | SF-36 | 62.7 | 50+ | Both | Healthy | 12 | Yes |
| El-Khoury F[ | 2015 | GH, MH, PF, VT | SF-36 | 79.8 | 65+ | Female | Fall risk | 104 | Yes |
| Canuto Wanderley FA[ | 2015 | BP, ERF, GH, MH, PF, PRF, SF, VT, PCS,MCS | SF-36 | 68.0 | 60+ | Both | Healthy | 32 | No |
| Brovold T[ | 2012 | BP, GH, MH, PF, SF, VT | SF-36 | 79.0 | 60+ | Both | Acute problem | 12 | Yes |
| Lincoln AK[ | 2011 | MCS | SF-36 | 67.1 | 60+ | Both | Diabetic | 16 | No |
| Sylliaas H[ | 2011 | MCS, PCS | SF-12 | 82.1 | 65+ | Both | Hip surgery | 12 | No |
| Mangione KK[ | 2010 | PF | SF-36 | 79.6 | 65+ | Both | Hip surgery | 10 | No |
| Kimura K[ | 2010 | BP, ERF, GH, MH, PF, PRF, SF, VT | SF-36 | 73.6 | 65+ | Both | Healthy | 12 | Yes |
| Teixeira LE[ | 2010 | BP, ERF, GH, MH, PF, PRF, SF, VT | SF-36 | 63.1 | 50+ | Female | PM/OP | 18 | No |
| McDermott MM[ | 2009 | PF | SF-36 | 71.7 | 60+ | Both | PAD | 24 | No |
Note. BP is bodily pain. ERF is emotional role functioning. GH is general health. MH is mental health. PF is physical functioning. PRF is physical role functioning. SF is social functioning. VT is vitality. MCS is mental component score. PCS is physical component score. PM is postmenopausal. OP is osteoporosis. PAD is peripheral arterial disease.
Physiotherapy Evidence Database (PEDro) scores for included meta-analysis studies
|
|
|
|
|
| Overall | 16 | 4.9 | 1.0 |
| Measure | |||
| BP | 7 | 4.3 | 1.1 |
| ERF | 6 | 4.2 | 1.2 |
| GH | 8 | 4.4 | 1.1 |
| MCS | 7 | 4.9 | 1.2 |
| MH | 8 | 4.4 | 1.1 |
| PCS | 7 | 5.1 | 1.2 |
| PF | 12 | 4.8 | 1.1 |
| PRF | 6 | 4.2 | 1.2 |
| SF | 7 | 4.3 | 1.1 |
| VT | 9 | 4.6 | 1.1 |
Note. N indicates number of studies. SD is standard deviation. PEDro scores can typically range from 0 to 10 but can only range from 0 to 7 in this research.
Figure 2
Figure 5Summary results and variance components across SF-36/12 component scores and dimensions
|
|
|
|
|
|
|
|
| Mental | ||||||
| MCS | 7 | 0.54 | 0.09-0.99 | 0.28 | 77.3 | 26.4 |
| ERF | 6 | 0.37 | -0.15-0.90 | 0.34 | 80.8 | 26.1 |
| MH | 8 | 0.64 | 0.30-0.99 | 0.18 | 79.7 | 34.4 |
| VT | 9 | 0.39 | 0.15-0.64 | 0.08 | 63.1 | 21.7 |
| SF | 7 | 0.29 | -0.04-0.61 | 0.11 | 62.8 | 16.1 |
| Physical | ||||||
| PCS | 7 | 0.50 | 0.07-0.94 | 0.27 | 80.2 | 30.3 |
| BP | 7 | 0.81 | 0.26-1.35 | 0.45 | 85.9 | 42.5 |
| GH | 8 | 0.57 | 0.19-0.94 | 0.22 | 83.4 | 42.2 |
| PRF | 6 | 0.64 | -0.05-1.33 | 0.65 | 88.5 | 43.4 |
| PF | 12 | 0.40 | 0.10-0.71 | 0.21 | 80.3 | 55.7 |
Note. N represents number of studies. Q statistic (with N-1 df) tests for heterogeneity. All Q P values were significant at P<0.01. τ2 represents variance component. I2 represents percent of heterogeneity.
Effect size by moderator for the SF-36 and SF-12 MCS and mental health dimensions
|
|
|
|
|
|
|
|
|
|
|
|
| Gendera | 0.761 |
|
| 0.788 | 0.866 | |||||
| Female | 0.41 | 0.28 | 0.91 | 0.49 | 0.43 | |||||
| Both | 0.58 | 0.85 | 0.11 | 0.31 | 0.38 | |||||
| Health Problema | 0.600 | 0.623 | 0.710 | 0.491 | 0.444 | |||||
| Yes | 0.69 | 0.56 | 0.36 | 0.07 | 0.49 | |||||
| No | 0.42 | 0.73 | 0.22 | 0.52 | 0.27 | |||||
| Multiplicitya | 0.819 | 0.561 | 0.091 |
| 0.582 | |||||
| RT only | 0.40 | 0.57 | 0.09 | -0.09 | 0.34 | |||||
| RT plus | 0.56 | 0.78 | 0.59 | 0.85 | 0.48 | |||||
| Age Groupa | 0.758 | 0.205 | 0.808 | 0.087 | 0.051 | |||||
| 50+ | 0.42 | 0.66 | 0.40 | 0.15 | 0.69 | |||||
| 60+ | 0.77 | 1.00 | 0.16 | 1.60 | 0.36 | |||||
| 65+ | 0.31 | 0.31 | 0.13 | 0.13 | 0.14 | |||||
| Lengthb | 0.726 | 0.054 | 0.818 |
| 0.097 | |||||
| Slope | -0.01 | -0.01 | -0.01 | 0.07 | -0.01 | |||||
| Ageb | 0.594 | 0.254 | 0.845 | 0.479 | 0.062 | |||||
| Slope | -0.02 | -0.02 | -0.01 | 0.05 | -0.03 | |||||
| PEDro Scoreb | 0.192 | 0.937 | 0.712 | 0.823 | 0.546 | |||||
| Slope | -0.25 | -0.02 | 0.06 | 0.06 | -0.08 |
Note. All values under HRQOL measures are ES. All moderator analyses were performed using random effects models with non-pooled variances (tau-squared). aThese moderators are treated as categorical with group-specific mean effect sizes reported. bThese moderators are treated as continuous with meta-regression coefficients reported. P values in bold are significant at P<0.05. P values underlined are suggestive at P<0.10.
Effect size by moderator for the SF-36 and SF-12 PCS and physical health dimensions
|
|
|
|
|
|
|
|
|
|
|
|
| Gendera | 0.524 | 0.671 | 0.652 |
| 0.644 | |||||
| Female | 0.29 | 1.00 | 0.71 | 1.48 | 0.30 | |||||
| Both | 0.59 | 0.73 | 0.50 | 0.25 | 0.47 | |||||
| Health Problema | 0.770 | 0.719 | 0.358 | 0.054 | 0.582 | |||||
| Yes | 0.57 | 0.68 | 0.40 | 1.38 | 0.34 | |||||
| No | 0.43 | 0.91 | 0.77 | 0.29 | 0.54 | |||||
| Multiplicitya | 0.063 |
|
| 0.185 | 0.366 | |||||
| RT only | 0.95 | 0.35 | 0.22 | 0.21 | 0.25 | |||||
| RT plus | 0.32 | 1.46 | 1.10 | 1.07 | 0.53 | |||||
| Age Groupa |
| 0.366 |
| 0.884 | 0.229 | |||||
| 50+ | 0.48 | 0.61 | 0.93 | 0.80 | 0.68 | |||||
| 60+ | 0.92 | 1.53 | 0.53 | 0.35 | 0.52 | |||||
| 65+ | -0.03 | 0.21 | 0.08 | 0.29 | 0.04 | |||||
| Lengthb | 0.345 |
| 0.298 | 0.802 | 0.943 | |||||
| Slope | 0.02 | 0.10 | -0.01 | 0.01 | 0.00 | |||||
| Ageb | 0.222 | 0.901 |
| 0.708 | 0.059 | |||||
| Slope | -0.04 | 0.01 | -0.05 | -0.03 | -0.04 | |||||
| PEDro Scoreb | 0.995 | 0.680 | 0.578 | 0.704 | 0.429 | |||||
| Slope | 0.00 | 0.12 | 0.12 | 0.14 | -0.13 |
Note. All values under HRQOL measures are ES. All moderator analyses were performed using random effects models with non-pooled variances (tau-squared). aThese moderators are treated as categorical with group-specific mean effect sizes reported. bThese moderators are treated as continuous with meta-regression coefficients reported. P values in bold are significant at P<0.05. P values underlined are suggestive at P<0.10.
Sensitivity analysis of effect sizes across SF-36 and SF-12 component scores and dimensions
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
|
| |
| Mental | |||||||||
| MCS | 0.59 | 0.557 | 0 | 0.54 | 0.09-0.99 | 0.28 | 0.06-0.50 | 0.64 | 0.13-1.15 |
| ERF | -0.37 | 0.712 | 0 | 0.37 | -0.15-0.90 | 0.16 | -0.25-0.57 | 0.56h | 0.06-1.06 |
| MH | 2.16 | 0.031 | 2 | 0.48 | 0.16-0.80 | 0.53 | 0.22-.84 | 0.74 | 0.50-0.98 |
| VT | 1.43 | 0.153 | 0 | 0.39 | 0.15-0.64 | 0.30 | 0.09-0.52 | 0.47 | 0.23-0.70 |
| SF | -0.55 | 0.579 | 1 | 0.37 | 0.04-0.71 | 0.16 | -0.06-0.38 | 0.37h | 0.06-0.69 |
| Physical | |||||||||
| PCS | -0.42 | 0.673 | 0 | 0.50 | 0.07-0.94 | 0.32 | 0.03-0.61 | 0.63 | 0.25-1.02 |
| BP | 0.55 | 0.582 | 0 | 0.81 | 0.26-1.35 | 0.57 | 0.15-0.99 | 0.95 | 0.37-1.53 |
| GH | 1.98 | 0.048 | 2 | 0.34 | -0.03-0.71 | 0.42 | 0.10-0.74 | 0.67 | 0.27-1.07 |
| PRF | -0.29 | 0.770 | 2 | 0.89 | 0.31-1.47 | 0.30i | 0.05-0.54 | 0.76 | -0.02-1.55 |
| PF | 0.83 | 0.408 | 0 | 0.40 | 0.10-.71 | 0.27 | 0.03-0.52 | 0.46 | 0.15-0.78 |
Note. aEgger’s regression models for testing funnel plot asymmetry. bTrim-and-fill method for estimating the number of effect sizes required to show a symmetric funnel plot. cLeave-one-out analysis re-estimating the effect sizes once for each study deleted. dNumber of effect sizes needed to balance the funnel plot. eEstimated mean effect size with imputed study effect sizes needed to balance funnel plot. fLowest ES seen from leave-one-out analysis. gHighest effect size seen from leave-one-out analysis. hIf Tomas-Carus (2016) is left out of the meta-analysis, both ERF (ES=0.56) and SF (ES=0.37) effects become significant. iIf Teixeira (2010) is left out of the meta-analysis, PRF (ES=0.30) effect becomes significant.